title: Association between C1019T polymorphism of the connexin37 gene and coronary heart disease in patients with in-stent restenosis.
abstract: Studies have shown that a C1019T polymorphism of the gene encoding the gap junction protein connexin37 is associated with coronary artery disease (CAD). The aim of the present study was to explore the association between the C1019T polymorphism in the connexin37 gene and CAD patients with in-stent restenosis (ISR). A total of 532 patients who had undergone coronary stenting and coronary angiography at least three months after the procedure were divided according to a clinical diagnosis standard into two groups which were ISR (n=67) and no in-stent restenosis (NISR; n=465) groups. A further 501 healthy individuals were controls. The subjects were genotyped by DNA sequencing. The results demonstrated the following: i) connexin37 gene 1019 sites in the population were distributed by polymorphism into three genetic types (CC, TC and TT types). The distribution frequency of the healthy control, ISR and NISR groups conformed to the Hardy-Weinberg genetic balance rule; ii) in comparison with the healthy controls, the frequency of the connexin37 C allele was higher in the CAD patients (57.05% vs. 41.32%; OR, 1.89; 95% CI, 1.58-2.25; P<0.01). The frequency of the C carriers (CC+TC) was 65.47% in the healthy controls, vs. 79.32% in CAD patients (P<0.01). The CAD risk was significantly increased in the carriers of the C allele (CC+TC) compared with TT homozygotes (OR, 2.03; 95% CI, 1.53-2.80; P<0.01). Stratified analysis demonstrated that a significant difference existed in the frequency of C carriers between the male CAD patients and healthy controls (79.63% vs. 72.45%; OR, 1.48; 95% CI, 1.06-2.09, P=0.02), as well as in the female CAD patients (78.00% vs. 51.50%; OR, 3.34; 95% CI, 1.90-5.86; P<0.01). In the female and male CAD patients, the frequency of the connexin37 C allele was higher than in the healthy controls (male: χ(2)=12.67, P<0.01; female: χ(2)=50.20, P<0.01); iii) compared with the NISR group, the frequencies of the connexin37 C allele and C carriers (CC+TC) were significantly higher in the ISR group (frequency of C allele: 72.39% vs. 54.84%; P<0.01; frequency of C carriers: 89.55% vs. 77.85%; P=0.03). Compared with TT homozygotes, the restenosis risk was significantly increased in the carriers of the C allele (CC+TC; OR, 2.44; 95% CI, 1.08-5.50). Subsequent stratified analysis revealed that the frequency of the C allele was significantly higher in the male ISR group than in the male NISR group (78.57% vs. 52.66%; OR, 3.30; 95% CI, 2.05-5.29; P<0.01). The restenosis risk was ∼four-fold higher in the C carriers (CC+TC) than in the TT homozygotes (OR, 3.74; 95% CI, 1.32-10.64). However in the female population, there was no difference in the ISR risk between the carriers of the C allele (CC+TC) and the TT homozygotes (P=0.70). In summary, the C allele of the connexin37 gene is not only is associated with the susceptibility to CAD, but also associated with restenosis following coronary stenting in the population studied herein, particularly the male population.
authors: Department of Cardiology, The Affiliated People's Hospital of Nanjing Medical University in Wuxi and People's Hospital of Wuxi City, Jiangsu, Wuxi 214023,  P.R. China.
authors: Su-Xia
authors: SX
authors: Guo
authors: Zhen-Yu
authors: ZY
authors: Yang
authors: Ru-Xing
authors: RX
authors: Wang
authors: Ying
authors: Y
authors: Yang
authors: Hua-Ming
authors: HM
authors: Cao
authors: Tao
authors: T
authors: Zhang
keywords: connexin37; coronary heart disease; gene polymorphism; in-stent restenosis
references: Am J Physiol Heart Circ Physiol. 2011 Nov;301(5):H1872-81
references: 21856908
references: J Clin Endocrinol Metab. 2012 Aug;97(8):2862-71
references: 22639289
references: J Intern Med. 1999 Aug;246(2):211-8
references: 10447790
references: Int J Cardiol. 2001 Dec;81(2-3):251-5
references: 11744143
references: Physiol Rev. 2003 Oct;83(4):1359-400
references: 14506308
references: J Mol Cell Cardiol. 2001 May;33(5):957-67
references: 11343418
references: Nat Med. 2006 Aug;12(8):950-4
references: 16862155
references: J Mol Cell Cardiol. 2012 Aug;53(2):299-309
references: 22659288
references: Dev Biol. 2011 Jun 15;354(2):253-66
references: 21515254
references: Curr Pharm Biotechnol. 2012 Jan;13(1):17-26
references: 21470165
references: Zhonghua Yi Xue Za Zhi. 2007 Jan 9;87(2):100-4
references: 17418016
references: Circulation. 1998 Jun 23;97(24):2396-401
references: 9641690
references: Int J Cardiol. 2005 Jul 10;102(2):269-71
references: 15982495
references: J Vasc Res. 2012;49(1):2-12
references: 21986401
references: N Engl J Med. 2002 Dec 12;347(24):1916-23
references: 12477941
references: Coron Artery Dis. 2012 Jan;23(1):57-61
references: 22133924
references: Clin Chem Lab Med. 2008;46(8):1102-8
references: 18605953
references: Atherosclerosis. 2007 Apr;191(2):355-61
references: 16677656
references: N Engl J Med. 2006 Feb 2;354(5):483-95
references: 16452560
references: Exp Ther Med. 2011 Mar;2(2):275-280
references: 22977497
references: J Histochem Cytochem. 2000 Oct;48(10):1377-89
references: 10990491
references: Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19347-52
references: 22087004
references: Thromb Haemost. 2009 Jun;101(6):1138-46
references: 19492159
references: J Gen Physiol. 2004 Nov;124(5):587-603
references: 15504903
references: Atherosclerosis. 2011 Jan;214(1):101-6
references: 21044781
references: J Am Coll Cardiol. 1993 Jan;21(1):6-14
references: 8417077
references: Exp Ther Med. 2012 Feb;3(2):314-318
references: 22969888